The U.S. Department of Health and Human Services (HHS) will provide approximately $590 million to Moderna to accelerate the development of mRNA-based pandemic influenza vaccines and enhance mRNA platform capabilities so that the U.S. is better prepared to respond to other emerging infectious diseases.
The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR).This funding allows Moderna to accelerate development of an H5N1 mRNA influenza vaccine that is well matched to strains currently circulating in cows and birds and expands the clinical data supporting the use of mRNA vaccines that may be needed if other influenza strains emerge with pandemic potential. (...)
In 2023, BARDA began working with Moderna to help develop mRNA vaccine to prepare for potential public health emergencies (PHEs) caused by influenza viruses, such as avian influenza A(H5N1).
In addition, Moderna will design and test an H7N9 mRNA pandemic influenza vaccine in a phase 3 clinical study. If successful, this vaccine potentially could become the first licensed for H7N9.
Moderna also will design up to four additional novel pandemic influenza vaccines and test preliminary safety and immunogenicity (generating an immune system response) in phase 1 clinical studies. This work will create the necessary background data to enable accelerated development of an mRNA vaccine targeted to various influenza virus subtypes of pandemic potential. This approach takes advantage of the versatility of Moderna’s mRNA platform, leveraging an existing manufacturing platform capability to support product development across multiple health threats.